Please login to the form below

Not currently logged in
Email:
Password:

Syneos Health announces partnership with AiCure

Will leverage proprietary intelligent software and AI-driven insights

Syneos Health

Syneos Health, an integrated biopharmaceutical solutions organisation, has partnered with AiCure for smarter clinical trials that optimise patient engagement. 

AiCure is an artificial intelligence and data analytics company, which offers proprietary intelligent software and AI-driven insights.

The partnership will see AiCure leverage Syneos’ behavioural insights-driven product development model, with the aim to capture, analyse and predict patient behaviours influencing clinical trial adherence.

“The AiCure platform aligns with our unique product developmet model that harnesses behavioural insights to unlock real world experiences,” said Alistair Macdonald, chief executive officer of Syneos Health.

“By deploying the AiCure platform to our investigative sites, we create insights-enriched patient communities to advance clinical research,” he added.

Syneos Health will have access to AiCure’s digital biomarker assessments, evaluating facial, verbal, speech and movement variables to objectively study known clinical endpoints.

The platform identifies adherence patterns and variations in site and participant engagement, providing the opportunity to modify behaviours that increase compliance for the improvement of overall trial success.

Part of this includes providing patients with a smartphone application to guide and confirm proper administration in real-time – as opposed to self-reporting measures.

“Syneos Health’s scale as a leading global CRO, and the largest contract commercial organisation, will enable valuable customer engagements and expands our reach with biopharmaceutical companies of all sizes,” said Adam Hanina, chief executive officer of AiCure

13th November 2019

From: Marketing

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
dna Communications

Healthcare communications with unique thinking, insight and attitude...

Latest intelligence

OPEN Health attend EB World Congress—building on momentum and strength in numbers for epidermolysis bullosa
Ben Speller shares his thoughts on the value of disease specific congresses...
OPEN Health use PR to support clinical trial recruitment
International Clinical Trials Day finds clinical research in the spotlight like never before, with any news coming from the many studies into potential vaccines and treatments for SARS-CoV-2...
Covid-19: what could it mean for the diabetic population?
Steve How and Oli Hudson, of Wilmington Healthcare, assess the scale of the diabetes crisis and how coronavirus might impact on it...

Infographics